Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to...

|About: Jazz Pharmaceuticals, Inc. (JAZZ)|By:, SA News Editor

Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to an FDA warning letter related to its Xyrem drug. However, Jefferies and Piper have come to Jazz's defense, with each noting that the warning merely involves the company's monitoring procedures, rather than any production issues.